Recenzija, prikaz
https://doi.org/10.20471/acc.2021.60.s3.07
Incidence of acute symptomatic seizures in patients with COVID-19: a single-center study
Ivana Šušak Sporiš
orcid.org/0000-0002-7812-4148
; Department of Neurology, Dubrava University Hospital, Zagreb, Croatia; Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; University of Applied Health Science in Zagreb, Zagreb, Croatia
Davor Sporiš
; Department of Neurology, Dubrava University Hospital, Zagreb, Croatia; Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; University of Applied Health Science in Zagreb, Zagreb, Croatia
Zrinka Čolak Romić
; Department of Neurology, Dubrava University Hospital, Zagreb, Croatia
Petra Bago Rožanković
; Department of Neurology, Dubrava University Hospital, Zagreb, Croatia; Chatolic University of Croatia, Zagreb, Croatia
Silvio Bašić
; Department of Neurology, Dubrava University Hospital, Zagreb, Croatia
Sažetak
The most common neurological symptoms in patients with SARS-CoV-2 infection
are headache, myalgia, encephalopathy, dizziness, dysgeusia and anosmia, making more than 90
percent of neurological manifestations of COVID-19. Other neurological manifestations such as
stroke, movement disorder symptoms or epileptic seizures are rare but rather devastating, with possible
lethal outcome. The primary aim of this study was to estimate the prevalence of acute symptomatic
seizures among COVID-19 patients, while secondary aim was to determine their possible etiology.
Out of 5382 patients with COVID-19 admitted to Dubrava University Hospital from November
1, 2020 until June 1, 2021, 38 (seizure rate 0.7%) of them had acute symptomatic seizures. Of these 38
patients, 29 (76.3%) had new-onset epileptic seizures and nine (23.7%) patients with previous epilepsy
history had breakthrough seizures during COVID-19. Although acute symptomatic seizures are
an infrequent complication of COVID-19, seizure risk must be considered in these patients, particularly
in the group of patients with a severe course of the disease. Accumulation of proinflammatory
cytokines may contribute to the occurrence of seizures in patients with COVID-19, but seizures may
also be secondary to primary brain pathology related to COVID-19, such as stroke or encephalitis.
Ključne riječi
Seizures; Epilepsy; COVID-19; SARS-CoV-2
Hrčak ID:
285130
URI
Datum izdavanja:
31.12.2021.
Posjeta: 624 *